Overview
“Window-dressing” is sometimes used as a term to describe a short-term strategy to make financial reports and portfolios look more appealing to investors. This might unfortunately imply a certain degree of puffery at best, or at worst, a certain amount of deception. But is that a fair characterisation of “window dressing?” Join our team of legal experts to find out more about this intriguing and how start-ups can benefit most from it.
Programme
4.00pm – 4:30pm: Registration and networking
4:30pm – 5:30pm: Experts sharing session on Window-dressing in M&A transactions (Jeffrey Lim and Frederick Tay)
5:30pm – 5:45pm: Launch of JATP's new practice group for start-ups
5:45pm – 6:30pm: Panel discussion and Q&A
6:30pm – 7:30pm: Networking and refreshments
Schedule
Date: 29 May 2025, Thursday
Time: 4:30 PM - 7:30 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: NSG Biolabs, 21 Biopolis Rd, #02-03/05, North Tower, Nucleos , 138567
Speakers
Speaker's Profile:
Frederick Tay, Director, Joyce A Tan & Partners
Frederick is with the firm’s corporate practice, specialising in mergers and acquisitions and corporate transactions. He has more than 10 years of experience in the healthcare and consumer healthcare industry. In the healthcare and life sciences industry, Frederick has advised and implemented both operational and transactional solutions for companies which include advising on supply contracts for active pharmaceutical ingredients in the manufacturing process, pricing and supply of medicines contracts with both public and private healthcare practices, advising on cross-border transactions globally, and advising on digital projects.
Speaker's Profile:
Jeffery Lim, Co-Managing Director, Joyce A Tan & Partners
Jeffrey specialises in intellectual property (IP), data protection, cybersecurity, data governance, and artificial intelligence, and he works with global big tech organisations, multinational corporations and companies in healthcare, financial services, e-commerce, and technology platforms. He has also advised foreign governments on data protection and security laws. Jeffrey helped develop the Singapore Computer Society’s (“SCS”) AI Ethics Body of Knowledge (“BOK”) and its second edition as its chief reviewer. He also help set up the world’s first AI Ethics professional certification in collaboration with SCS and IMDA. He is an honorary legal advisor to the Singapore Computer Society. He formerly chaired the Singapore Law Society Cybersecurity and Data Protection Committee and remains an active committee member. He has also co-authored numerous articles include for the Singapore PDPC and has published articles on artificial intelligence, data privacy, data exchanges and IP.
Speaker's Profile:
Abel Ang, President & Chief Executive Officer, Advanced MedTech Holdings
Abel Ang is the founding President & CEO of Advanced MedTech Holdings, a US$335M global urology leader. Under his leadership, the company quadrupled revenue and grew EBITDA 33-fold. He has launched over 100 medical devices globally and was Senior Advisor to the CEO of Greatbatch (NYSE: ITGR). Previously, he was President, Asia/Pacific and CTO at Hill-Rom (now part of Baxter), overseeing global R&D and a US$420M business unit. He led Singapore’s medtech/biotech sector at EDB. Ang serves on boards including Advanced MedTech, SonoMotion, ABM Respiratory, AWAK Technologies (Chair), and was on Aslan Pharmaceuticals (NYSE: ASLN). He teaches in MBA programs at NTU and Waseda, chairs Republic Polytechnic, and sits on the board of Singapore Institute of Management. He holds an MSc in Computational Biology (Rutgers), attended HBS AMP, and received two Public Service Medals for his industry and COVID-19 contributions.
Speaker's Profile:
Dr Rosemary Tan, Chief Executive Officer, CoV Biotechnology
Dr Rosemary Tan is the Chief Executive Officer of Leyden Labs Asia. She received her BSc from the University of Calgary, Canada before going to the Institute of Cell and Molecular Biology, Osaka University and the Department of Immunology at the Medical School in the University of Tokyo. She obtained her PhD from NUS. Dr Tan founded Veredus Laboratories and led its successful acquisition by Sekisui Chemical. Under her leadership, Veredus supported national responses to H1N1 and COVID-19. She later led CoV Biotechnology, a Singapore-based firm developing broad-spectrum coronavirus vaccines and therapeutics, which was acquired by Leyden Labs, a Dutch clinical-stage biotech focused on respiratory viruses. Leveraging her strong network in the region, Dr Tan continues to lead the team as Leyden Labs Asia, to deliver Leyden Labs’ vision of combating respiratory viruses and strengthening global health resilience.
Moderator's Profile:
Dr Lim Jui, Chief Executive Officer, SGInnovate
Dr Lim Jui is CEO of SGInnovate, where he leads efforts to build a Deep Tech economy by supporting entrepreneurial scientists through investments, ecosystem access, and talent development. Trained in medicine, Jui has spent most of his career in science and innovation, previously serving as Director of Investments at Bio*One Capital, CEO of Merlin MD, Executive Director of MERCI at NUS, and Programme Director of Singapore-Stanford Biodesign. Before SGInnovate, he was CEO of NTUitive, NTU’s innovation arm. He currently serves on the boards of directors of the Intellectual Property Office of Singapore (IPOS), IPOS International, the business arm of IPOS, and several start-up companies. Jui received his BA in Biological Sciences and East Asian Studies and his MD from Columbia University, followed by a Master of Medicine in Anaesthesiology and Surgical Intensive Care from the National University of Singapore. He remains a registered medical practitioner in Singapore.
